MarketPulse

biosimilars

3 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Investor Bet on Organon Stock Signals Turnaround Faith Despite 61% Collapse

Sio Capital Management invested $24.53 million in Organon ($OGN) at $6.03/share, betting on turnaround potential despite 61% annual decline. Company maintains flat 2026 guidance with $1.9B adjusted EBITDA.
OGNvalue investinginstitutional investment
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Neumega Poised for Robust Growth Through 2030 as Oncology Demand Surges

Pfizer's Neumega faces robust growth through 2030 driven by rising cancer diagnoses, chemotherapy intensification, and expanding oncology infrastructure globally.
PFEpersonalized medicineAsia Pacific growth
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Biopharmaceutical CMO Market Set to Quadruple to $76.2B by 2035

Biopharmaceutical CMO market to grow from $21.16B in 2025 to $76.2B by 2035, driven by outsourcing demand and capacity constraints.
TMOLZAGYWXXWYbiologicsmonoclonal antibodies